Kamel Djazouli

Dr. Kamel Djazouli is a medical oncologist with over 25 years of experience in solid tumor cancer fields, where he specializes in late-stage clinical development and Medical Affairs. Dr. Djazouli has been involved in the development, approval, and launch of multiple new drugs, including the recent new standard of care therapies for treatment of breast, lung, and pancreatic cancers. Recognized for his innovative launch strategies, Dr. Djazouli has managed many product launches in Europe for breast cancer, brain tumors, ovarian cancer, head and neck cancers, and malignant melanoma. Dr Djazouli is renowned for his market knowledge and close contact with key opinion leaders in the industry. Before joining Immunicom, Dr. Djazouli served as global head of Medical Affairs for oncology at Celgene. He has also served as a medical lead consultant and expert advisor to several international companies.

Dr. Djazouli received his medical training and doctorate degree from University of Algiers (Algeria) and Rene Descartes, Paris-St Louis University Hospital (France). He was trained at the Gustave Roussy Cancer Institute in Villejuif (France), where he practiced Oncology before establishing his professional expertise in the healthcare industry.